Publications by authors named "Ana Cabranes"

Claim this Profile
C
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
Eva de Lago, Miguel Moreno-Martet, Ana Cabranes, José A Ramos, Javier Fernández-Ruiz

Neuropharmacology· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice.
Ana Cabranes, Gareth Pryce, David Baker, Javier Fernández-Ruiz

Brain Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Eva de Lago, Javier Fernández-Ruiz, Silvia Ortega-Gutiérrez, Ana Cabranes, Gareth Pryce

Eur Neuropsychopharmacol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Ana Cabranes, Katerina Venderova, Eva de Lago, Filomena Fezza, Antonio Sánchez

Neurobiol Dis· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake.
Eva de Lago, Alessia Ligresti, Giorgio Ortar, Enrico Morera, Ana Cabranes

Eur J Pharmacol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis